A detailed history of Goldman Sachs Group Inc transactions in Pharvaris N.V. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 63,830 shares of PHVS stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,830
Previous 61,470 3.84%
Holding current value
$1.18 Million
Previous $1.16 Million 2.34%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.73 - $21.4 $37,122 - $50,504
2,360 Added 3.84%
63,830 $1.18 Million
Q2 2024

Aug 13, 2024

BUY
$15.67 - $24.59 $475,647 - $746,404
30,354 Added 97.55%
61,470 $1.16 Million
Q1 2024

May 15, 2024

BUY
$21.26 - $32.07 $479,774 - $723,723
22,567 Added 263.97%
31,116 $719,000
Q4 2023

Feb 13, 2024

BUY
$15.2 - $28.05 $129,944 - $239,799
8,549 New
8,549 $239,000
Q3 2022

May 14, 2024

SELL
$7.67 - $25.8 $2,646 - $8,901
-345 Reduced 0.61%
56,606 $434,000
Q3 2022

Nov 10, 2022

SELL
$7.67 - $25.8 $2,646 - $8,901
-345 Reduced 0.61%
56,606 $434,000
Q2 2022

May 14, 2024

BUY
$16.35 - $27.5 $791,372 - $1.33 Million
48,402 Added 566.17%
56,951 $1.26 Million
Q2 2022

Aug 15, 2022

BUY
$16.35 - $27.5 $18,230 - $30,662
1,115 Added 2.0%
56,951 $1.26 Million
Q1 2022

May 16, 2022

SELL
$15.98 - $19.65 $26,846 - $33,012
-1,680 Reduced 2.92%
55,836 $1.01 Million
Q4 2021

Feb 14, 2022

BUY
$13.28 - $18.0 $363,101 - $492,156
27,342 Added 90.61%
57,516 $828,000
Q3 2021

Nov 10, 2021

BUY
$13.14 - $20.97 $396,486 - $632,748
30,174 New
30,174 $535,000

Others Institutions Holding PHVS

About Pharvaris N.V.


  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $625M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.